The First Affiliated Hospital,Sun Yat-sen University
Guangzhou, Guangdong, 510080, China
Location status: Recruiting
NCT Number: NCT02954419
This prospective cohort study is designed to examine the association between blood and urine biomarkers (including genetic variants) and long-term kidney disease progression among 2000 Chinese IgA nephropathy patients with relatively normal kidney function (eGFR≥60 ml/min/1.73 m2).
Interested in participating?
Request Info14 year and older
All sexes
Observational
Guangzhou, Guangdong, 510080, China
Location status: Recruiting
Glomerulonephritis is the leading cause of end-stage renal disease (ESRD) in China, where IgA nephropathy (IgAN) is the most common primary glomerulonephritis among individuals undergoing renal biopsy. The outcomes of IgAN vary highly among individuals; some have the stable renal function for lifetime and some quickly progress to ESRD. No biomarker is widely applied to predict the outcomes in IgAN yet. Previous GWAS studies including ours have identified some susceptibility loci associated with the development and clinical features of IgAN. In addition, a few cohort studies have revealed several genetic loci related to the progression of IgAN. But, all of the reported GWAS studies were based on a case-control design, which may not provide the information about the effect of genetic variants on the progression of disease. Previous cohort studies which focused on certain specific candidate genes cannot unbiasedly explore the progression related susceptibility loci. Furthermore, there is no study that integrates the information from whole genomic loci and serum and urine biomarkers to predict the long-term progression in IgAN. Therefore, we design a relative large prospective cohort study to examine the association between blood and urine biomarkers (including whole genomic loci) and long-term kidney disease progression among 2000 Chinese IgAN patients with relatively normal kidney function (eGFR≥60 ml/min/1.73 m2).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
No intervention
Time frame: 120 months
Time frame: 120 months
Time frame: 120 months
Time frame: 120 months
Contact information is provided by the study sponsor or research team.
Sun Yat-sen University
Other
Acronym: INTEREST
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02529722
Autoimmune Diseases, Female Urogenital Diseases
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT07498335
Autoimmune Diseases, Berger Disease
Neptune City, New Jersey, United States
View Trial DetailsNCT07541287
Autoimmune Diseases, Female Urogenital Diseases
Chula Vista, California, United States
View Trial DetailsNCT07010250
ANCA Associated Vasculitis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Paris, France
View Trial Details